`
`(Reference Data of Financial Statements Fiscal 2016 1st Quarter)
`
`August 3, 2016
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
` Corporate Communications
` Tel:
` +81-(0)3-5977-5002
` Fax:
` +81-(0)3-5977-5131
` Email:
` koho@kaken.co.jp
`
`Page 1 of 2
`
`ACRUX DDS PTY LTD. et al.
`
`EXHIBIT 1649
`
`IPR Petition for
`
`U.S. Patent No. 7,214,506
`
`
`
`1. Summary of Consolidated Financial Statements for Fiscal 2016 1st Quarter
`
`( Figures less than one million yen have been omitted)
`
`FY2015
`1st Q
`
`FY2015
`
`FY2016
`1st Q
`
`Y o Y increase (decrease)
`
`Yen
`
`%
`
`Plan
`FY2016
`
`Y o Y increase (decrease)
`
`Yen
`
`%
`
`Net sales
`
`
`
`27,633
`
`
`
`109,730
`
`
`
`26,228
`
`(1,405)
`
`
`
`94.9% 106,100
`
`(3,630)
`
`Operating income
`
`
`
`9,234
`
`
`
`35,146
`
`
`
`8,097
`
`(1,136)
`
`87.7%
`
`
`
`28,900
`
`(6,246)
`
`96.7%
`
`82.2%
`
` Ratio of net sales
`
`33.4%
`
`32.0%
`
`30.9%
`
`27.2%
`
`Ordinary income
`
`
`
`9,362
`
`
`
`35,365
`
`
`
`8,217
`
`(1,145)
`
`87.8%
`
`
`
`29,100
`
`(6,265)
`
`82.3%
`
` Ratio of net sales
`
`33.9%
`
`32.2%
`
`31.3%
`
`27.4%
`
`Net income
`
`
`
`6,300
`
`
`
`21,143
`
`
`
`5,796
`
`(503)
`
`92.0%
`
`
`
`20,800
`
`(343)
`
`98.4%
`
` Ratio of net sales
`
`22.8%
`
`19.3%
`
`22.1%
`
`19.6%
`
`(1,301)
`
`79.8%
`
`Comprehensive income
`
`
`
`6,460
`
`
`
`18,444
`
`
`
`5,158
`
`R&D expenses
`
`
`
`1,408
`
`
`
`5,883
`
`
`
`1,899
`
`490
`
`134.8%
`
`
`
`10,200
`
`4,317
`
`173.4%
`
`2. Breakdown of Sales by Main Pharmaceuticals and Medical Devices
`
`( Figures less than one million yen have been omitted)
`
`FY2015
`1st Q
`
`FY2015
`
`FY2016
`1st Q
`
`%
`
`Plan
`FY2016
`
`%
`
`8,020
`
`30,760
`
`7,754
`
`96.7%
`
`29,300
`
`95.3%
`
`4,499
`
`19,868
`
`5,796
`
`128.8%
`
`23,800
`
`119.8%
`
`2,714
`
`11,262
`
`2,701
`
`99.5%
`
`11,500
`
`102.1%
`
`1,123
`
`4,526
`
`1,133
`
`100.8%
`
`4,300
`
`95.0%
`
`924
`
`3,617
`
`941
`
`101.9%
`
`3,700
`
`102.3%
`
`Anti-osteoarthritis
`Artz
`
`Anti-nail fungus
`
`Clenafin
`
`Post-operative anti-adhesive
`Seprafilm
`
`Anti-hyperlipidemia
`Lipidil
`
`Wound healing agent
`Fiblast Spray
`
`Generic products
`
`3,330
`
`13,292
`
`3,045
`
`91.4%
`
`12,700
`
`95.5%
`
`Sales of Jublia*
`
`1,717
`
`5,722
`
`1,033
`
`60.2%
`
`4,100
`
`71.7%
`
`(*including sales of API and finished product, royalty revenue, milestone revenue and initial payment)
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
`Page 2 of 2
`
`